Xie H, Hata K, Lu M, Kong Q, Miyazaki K
Department of Ultrasound, First Affiliated Hospital of Sum Yat-sen University of Medical Sciences, Guangzhuo, China.
Int J Gynaecol Obstet. 1999 Jun;65(3):281-6. doi: 10.1016/s0020-7292(99)00033-8.
To assess the reliability of color Doppler energy (CDE) and a related quantitative analysis for detection and follow-up of uterine involvement in gestational trophoblastic tumor.
CDE was performed in 19 patients with trophoblastic tumor, in 25 women in early pregnancy and 25 non-pregnant women. The blood flow area ratio (BFAR) in CDE was used as an index representing uterine involvement. In nine of the 19 patients, BFAR was measured before, during and at termination of chemotherapy.
The BFAR (mean +/- S.D.) of uterine profiles in 19 patients (39.9 +/- 1.3%) was significantly higher than that in 25 pregnant women (24.6 +/- 10.1%, P = 0.002) and in 25 non-pregnant women (14.8 +/- 5.7%, P = 0.001). In the follow-up of nine patients, when beta-hCG was less than 3.1 ng/ml during the treatment, the BFAR (38.7 +/- 11.9%) decreased below that (44.2 +/- 14.6%) seen prior to treatment (P = 0.009) and was much lower at termination of treatment (27.5 +/- 12.3%, P = 0.048).
These data support the use of CDE and the related quantitative analysis as a new method for detecting and follow-up of uterine involvement in patients with trophoblastic tumors.
评估彩色多普勒能量图（CDE）及其相关定量分析在妊娠滋养细胞肿瘤子宫受累检测及随访中的可靠性。
对19例滋养细胞肿瘤患者、25例早孕女性及25例非孕女性进行CDE检查。将CDE中的血流面积比（BFAR）作为代表子宫受累的指标。在19例患者中的9例，于化疗前、化疗期间及化疗结束时测量BFAR。
19例患者子宫轮廓的BFAR（均值±标准差）为39.9±1.3%，显著高于25例孕妇（24.6±10.1%，P = 0.002）及25例非孕女性（14.8±5.7%，P = 0.001）。在9例患者的随访中，治疗期间β-hCG小于3.1 ng/ml时，BFAR（38.7±11.9%）低于治疗前（44.2±14.6%，P = 0.009），且在治疗结束时更低（27.5±12.3%，P = 0.048）。
这些数据支持将CDE及其相关定量分析作为检测和随访滋养细胞肿瘤患者子宫受累情况的一种新方法。
